Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 vs chemotherapy in advanced esophageal squamous cell carcinoma after first-line failure
CTR20170307Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui Therapeutics. Started Apr 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20170307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170307.